Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alzamend Neuro Inc
(NQ:
ALZN
)
0.7110
+0.0010 (+0.14%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alzamend Neuro Inc
< Previous
1
2
Next >
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
December 11, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
November 22, 2022
Via
ACCESSWIRE
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
September 22, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
November 20, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
November 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
November 13, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Reverse Stock Split
October 30, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
October 23, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
October 02, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
September 22, 2023
From
Alzamend Neuro
Via
Business Wire
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
August 30, 2023
From
Alzamend Neuro
Via
Business Wire
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
June 22, 2023
From
Alzamend Neuro
Via
Business Wire
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference
June 13, 2023
From
Alzamend Neuro
Via
Business Wire
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 04, 2023
From
Ault Alliance, Inc.
Via
Business Wire
KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 03, 2023
Via
Business Wire
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 03, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
March 22, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
March 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro to Present at Sequire Biotechnology Conference
January 26, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
January 04, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
December 28, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
November 15, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
October 31, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
October 05, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
September 29, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
July 18, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
June 03, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
May 17, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
May 05, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
April 28, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.